Heart failure & cardiomyopathiesCase-control study
Myocardial Fibroblast Activation in Ischemic and Nonischemic Cardiomyopathy
- Prospective case-control study
- Data analysis January 2024 to January 2025
Authors' conclusion
In this case-control study, patients with heart failure demonstrated persistent myocardial fibroblast activation with distinct spatial patterns according to cardiomyopathy etiology.
Study context
- Population
- Patients with HFrEF, patients with prior MI without HF, and healthy volunteers undergoing [68Ga]FAPI-46 positron emission tomography (PET)/magnetic resonance imaging (MRI)42 with HF
- Participants
- 81 patients
- Comparison
- HFrEF vs prior MI without HF vs healthy volunteers
- Outcome
- Myocardial fibroblast activation quantified by [68Ga]FAPI-46 SUVmax
Main finding
As reported in the abstract
All HF
2.7
mean · SD 1.5
Healthy volunteers
1.5
mean · SD 0.3
Ischemic cardiomyopathy
3.2
mean · SD 1.1
Nonischemic cardiomyopathy
2.3
mean · SD 0.5
Prior MI
2.5
mean · SD 0.3
All HF vs Healthy volunteers: P < 0.001 · Ischemic cardiomyopathy vs Prior MI: P = 0.03
Observational data: associations, not effects.
Further findings
Baseline uptake vs improvement in EF with optimal medical therapy (HF, repeat imaging >6 months) · more than 6 months
- Higher baseline uptake associated with less EF improvement (r)
- −0.52
- P
- P = 0.02
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Summarised from the published abstract; every number is checked against it